Pyxis Oncology Q3 2026 Results: Net Loss of $20M, Loss Narrows
Pyxis Oncology reported a net loss of $68.6 million for the nine months ended September 30, 2026, compared to $61.5 million in the prior year. The company remains in the clinical stage, heavily dependent on its lead product candidate micvotabart pelidotin (MICVO), and recently completed a private placement of common stock to raise approximately $48.3 million.
- Key figure
- Net loss $20M